Simulations Plus, Inc. (SLP) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed outlook. While there is positive news about software performance peaking and MedCom exceeding expectations, challenges exist with clinical operations software revenue and tough comparisons. The Q&A section reveals cautious optimism with no change in guidance and AI integration showing promise. However, management's avoidance of specific details and the lack of new verticals or products in the near term suggest limited immediate catalysts. Consequently, the stock is likely to remain neutral over the next two weeks.
Key Financial Performance
Total Revenue $18.4 million, a decrease of 3% year-over-year. The decline was attributed to market conditions and client consolidations.
Software Revenue Decreased 17%, representing 48% of total revenue. The decline was due to market conditions and client consolidations.
Services Revenue Increased 16%, representing 52% of total revenue. The increase was primarily due to strong contributions in the MedCom business.
Discovery Revenue Increased 3% for the quarter and for the trailing 12-month period. No specific reasons for the increase were mentioned.
Development Revenue Declined 6% for the quarter but grew 1% for the trailing 12-month period. The decline was attributed to market conditions and client consolidations.
Clinical Operations Revenue Declined 82% for the quarter and 28% for the trailing 12-month period. The decline was attributed to market conditions and client consolidations.
Services Backlog Increased 18% to $20.4 million from $17.3 million last year. The increase was due to a healthy pipeline of services projects.
Development Services Revenue Grew 8% during the quarter but declined 5% for the trailing 12-month period. No specific reasons for the changes were mentioned.
Commercialization Services Revenue Grew 42% during the quarter and 191% for the trailing 12-month period. The increase was primarily due to strong contributions in the MedCom business.
Total Gross Margin 59%, compared to 54% in the prior period. The increase was due to lower clinical operations revenue and reorganization of services personnel to support product development efforts.
Software Gross Margin 84%, compared to 75% in the prior period. The increase was due to lower clinical operations revenue.
Services Gross Margin 36%, compared to 26% in the prior period. The increase was due to the prior year reduction in force and reorganization of services personnel to support product development efforts.
Other Income $0.3 million, compared to $0.1 million last year. The increase was primarily due to higher interest income.
Income Tax Expense $0.3 million, compared to $0.1 million last year. The increase was due to a higher effective tax rate of 30% compared to 24% last year.
Cash and Short-term Investments $35.7 million, with no debt and strong free cash flow. No specific reasons for the cash position were mentioned.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Integrated Product Ecosystem: Advancing progress towards a unified ecosystem combining validated science, cloud-scale performance, and AI grounded in regulatory-grade modeling.
AI-driven Services: Developing intelligent tools for data curation, simulation analysis, and regulatory-compliant reporting.
Product Interoperability: Seamless integration across products like GastroPlus, MonolixSuite, ADMET Predictor, and QSP platforms.
Client Base and Revenue: 302 commercial clients with an average revenue per client of $97,000 for the quarter and $147,000 on a trailing 12-month basis.
Services Revenue Growth: Services revenue increased by 16%, driven by strong contributions from MedCom business.
Gross Margin Improvement: Total gross margin increased to 59% from 54% in the prior period, with software gross margin at 84% and services gross margin at 36%.
Cash Position: Ended the quarter with $35.7 million in cash and short-term investments, no debt, and strong free cash flow.
Strategic Acquisitions: Focused on broadening reach and impact through acquisitions and investment in science.
Unified Operating Model: Transitioning to a fully integrated ecosystem supporting discovery, development, clinical operations, and commercialization.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decrease: Total revenue decreased by 3% in the first quarter, with software revenue declining by 17%. This decline could impact the company's financial performance and growth objectives.
Client Consolidations: Client consolidations and market conditions negatively impacted software revenue and renewal rates, posing a challenge to maintaining consistent revenue streams.
Clinical Operations Revenue Decline: Clinical operations revenue declined significantly by 82% for the quarter and 28% for the trailing 12-month period, which could hinder the company's ability to sustain its clinical operations segment.
Development Revenue Decline: Development revenue declined by 6% for the quarter, which may affect the company's ability to grow its development-related offerings.
Economic and Market Conditions: Market conditions, including client spending patterns and consolidations, continue to pose challenges to revenue growth and operational stability.
Tax Rate Increase: The effective tax rate increased from 24% to 30%, which could reduce net income and impact financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for Fiscal Year 2026: Total revenue is projected to be between $79 million to $82 million, representing year-over-year revenue growth of 0% to 4%.
Revenue Mix: Software revenue is expected to constitute 57% to 62% of total revenue.
Adjusted EBITDA Margin: The adjusted EBITDA margin is anticipated to range between 26% to 30%.
Adjusted Diluted Earnings Per Share: Expected to be between $1.03 to $1.10 for fiscal year 2026.
Second Quarter Revenue: Revenue is anticipated to be approximately $21 million to $22 million.
Market Trends and Client Spending: An uptick in client spending is observed, particularly in the Services segment, which is expected to precede an increase in software activity.
Strategic Focus for Fiscal 2026: The company aims to advance an integrated product ecosystem combining validated science, cloud-scale performance, and AI-driven tools to enhance client efficiency and regulatory compliance.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the positive commentary regarding most favored nations, lower tariff risk, and their impact on customer budgets and R&D allocations?
A:Shawn O'Connor explained that agreements on most favored nation pricing and reduced tariff discussions, such as the U.K. agreement, have stabilized client outlooks. This led to increased activity in budget discussions and proposals, which translated into robust service revenue delivery in the November quarter. Optimism for 2026 is high, though cautious.
Q:Why was the performance of DILIsym QSP software softer compared to GastroPlus and ADMET predictor?
A:Shawn O'Connor noted that QSP software licensing is primarily driven by therapeutic models sold on a perpetual license basis. The first quarter of the previous year had exceptionally high sales of QSP models, creating a tough comparison. While QSP software revenue met expectations, its growth is lumpy due to the nature of perpetual licenses.
Q:Can you provide insights into the expected software and service mix for the remaining quarters and what will drive software performance?
A:Shawn O'Connor stated that there is no change in the guidance range for software-service mix (57%-62% software contribution). The first quarter's strong service performance does not alter the outlook. Software revenue is expected to peak in the second and third quarters due to seasonality and renewals. Accelerated client spending on services may lead to subsequent software upsells.
Q:Did the consolidation of large pharma impact software renewals in the first quarter, and how does it compare to historical trends?
A:Shawn O'Connor mentioned that consolidation is a factor in renewal rates but had no major impact in the first quarter. The uptick in acquisitions is mostly large pharma acquiring smaller biotech assets, which are not significant software license holders. The outlook for 2026 does not anticipate significant consolidation-related impacts.
Q:Does the improved environment and backlog momentum affect the cadence of guidance, making it less back-weighted?
A:Shawn O'Connor explained that while the year-over-year growth percentage may appear back-weighted due to tough comparisons in the first half, the absolute dollar flow follows historical seasonality patterns. The back half of the year will show stronger year-over-year growth due to easier comparisons.
Q:How is the MedCom business performing, and does it affect proficiency software comps?
A:Shawn O'Connor noted that MedCom's performance exceeded expectations in the first quarter, reflecting increased client spending. However, proficiency software platform revenue remains challenged due to tough year-over-year comparisons.
Q:Why is services considered a leading indicator for software demand, and how does it apply to the current setup?
A:Shawn O'Connor clarified that as clients increase budgets, they can quickly initiate service projects, which may later lead to software upsells as they expand modeling departments. The current uptick in service bookings suggests a broader increase in client budgets, potentially benefiting software demand.
Q:What is the impact of reallocating services personnel to product development on the P&L, and is it temporary or permanent?
A:Shawn O'Connor explained that the reallocation is part of a reorganization to improve service margins and accelerate product development. This has increased R&D expenses, which are expected to average 15%-17% of revenue for the year. The shift is aligned with the integrated product strategy and is more permanent in nature.
Q:Can you provide more details on the commercialization services growth and its relation to proficiency?
A:Shawn O'Connor stated that commercialization services, specifically medical communications, performed above expectations in the first quarter. This growth reflects increased client spending and is tied to the proficiency acquisition, which brought both software and service revenue streams.
Q:Why did clinical operations software revenue decline year-over-year, and was it expected?
A:Shawn O'Connor explained that the decline in clinical operations software revenue, specifically the proficiency training platform, was due to strong contributions in the first half of fiscal 2025 and challenges in clinical trial startups. The year-over-year decline was expected and aligns with fiscal 2026 guidance.
Q:What is the status of AI integration with the core platform, and how does it impact pricing and renewals?
A:Shawn O'Connor reported favorable client responses to initial AI features released with GastroPlus. The integration has allowed for more aggressive pricing and will contribute to future monetization opportunities. Further details will be shared at the upcoming Investor Day.
Q:Are there plans to launch new verticals or products within the existing platform in the next 12-18 months?
A:Shawn O'Connor stated that the focus remains on drug development and related areas. While new revenue streams may emerge from the product ecosystem, significant impacts on fiscal 2026 revenue are not anticipated and are already included in guidance.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the impact of AI integration on pricing flexibility and license renewals, as well as the exact timeline and revenue implications of new product launches within the existing platform. Additionally, responses regarding the profitability impact of reallocating services personnel to product development lacked precise numerical data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CFO Executive
Clinical month
Commercialization Services
Copilots module
Corporate Secretary
Development Services
Development month
Development product
Discovery month
Discovery product
Executive VP
FDA NAM
MedCom Development
MedCom service
NAM guideline
New line
Plus science
Relations measure
Secretary Software
Services month
Services segment
Services software
Software Services
VP Corporate
Welcome Simulations
acceleration end
activity priority
client renewal
ecosystem
increase software
margin service
month basis
month period
ops product
period service
service contribution
service margin
software margin
SLP Transcript
Simulations Plus, Inc. (SLP) Q2 2026 Earnings Call Transcript
Unknown4-9
The earnings call reveals mixed signals: strong software and services margins, new customer acquisitions, and a healthy cash position are positive. However, the cautious revenue guidance, increased tax expense, and lack of AI monetization in FY '26 are concerns. The Q&A highlighted uncertainties in guidance adjustments and macroeconomic factors, tempering optimism. These factors suggest a neutral stock price movement over the next two weeks.
Simulations Plus, Inc. (SLP) Q1 2026 Earnings Call Transcript
Unknown1-8
The earnings call summary presents a mixed outlook. While there is positive news about software performance peaking and MedCom exceeding expectations, challenges exist with clinical operations software revenue and tough comparisons. The Q&A section reveals cautious optimism with no change in guidance and AI integration showing promise. However, management's avoidance of specific details and the lack of new verticals or products in the near term suggest limited immediate catalysts. Consequently, the stock is likely to remain neutral over the next two weeks.
Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript
Unknown12-1
The earnings call summary and Q&A session reveal a mixed outlook. Positive elements include stable fiscal year '26 guidance, potential growth from AI capabilities, and interest in acquisitions. However, challenges such as a significant drop in Pro-ficiency software revenue, cautious large pharma, and current renewal rates in the low to mid-80% range offset these positives. The lack of significant changes in guidance assumptions and the absence of major cancellations provide stability, but the overall sentiment remains neutral due to the balancing of positive and negative factors.
Simulations Plus, Inc. (SLP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral9-11
SLP Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
